Lincoln Pharmaceuticals Limited Stock Price Today (NSE: LINCOLN)

Lincoln Pharmaceuticals Limited

590.7011.90 (1.97%)
Market Closed

Fundamental Score

...

Lincoln Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Lincoln Pharmaceuticals Limited share price today is 590.70, down 1.97% on NSE/BSE as of 16 September 2026. Lincoln Pharmaceuticals Limited (LINCOLN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 1.18K (Cr). The 52-week high for LINCOLN share price is 770.00 and the 52-week low is 440.00. At a P/E ratio of 12.27x, LINCOLN is currently trading below its industry average P/E of 34.89x. 0

Lincoln Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
648.40
Low
576.30
Volume
81.8K
Change
+6.69%

Lincoln Pharmaceuticals Limited share price chart: 6.69% return over the past month. 52-week high ₹770.00, 52-week low ₹440.00.

Lincoln Pharmaceuticals Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
606.65609.95586.10590.7033.11K (Cr)
625.05630.90600.00602.6062.53K (Cr)
635.00635.00619.10623.5034.33K (Cr)
641.60647.05631.00634.4027.78K (Cr)
639.90642.90632.35637.5031.33K (Cr)
637.35648.40633.45639.801.11L (Cr)
626.80640.00617.70632.3575.01K (Cr)
627.00631.00618.00620.8029.09K (Cr)
627.35627.35619.00622.6522.96K (Cr)
611.30629.45605.40618.3556.38K (Cr)

Lincoln Pharmaceuticals Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
613.00648.40586.10590.70-3.64%
578.90646.95572.00606.75+4.81%
633.20635.95569.70577.15-8.85%
632.95659.45585.10623.50-1.49%
647.00770.00620.00632.95-2.17%
575.00733.00545.00645.80+12.31%
605.50651.45560.40564.95-6.70%
458.75677.00452.90631.05+37.56%
485.20505.00440.00456.45-5.93%
510.00515.00464.40483.95-5.11%
530.50542.90490.00511.95-3.50%
531.00545.00518.00529.80-0.23%

Returns & Performance

Poor

Return on Equity (ROE)

0.00%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

15.87%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

19.69%

Average operating profit margin over 5 years

Dividend Yield

0.30%

Annual dividend as % of current share price

Lincoln Pharmaceuticals Limited Valuation Check

Excellent

Price to Earnings (P/E)

12.27x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

49.78%

% shares held by company founders/management

Poor

FII Holding

4.60%

% shares held by foreign institutional investors

Poor

DII Holding

0.27%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

0.43%

Net profit growth vs same quarter last year

Average

Revenue Growth (Quarterly YoY)

15.07%

Revenue growth vs same quarter last year

Average

Revenue Growth (5-Year CAGR)

10.19%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

7.76%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

7.11%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

115.14x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

233.89 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Lincoln Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of LINCOLN across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Excellent ROCE Performance (15.87%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (19.69%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 12.27 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (15.07%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (115.14x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 4.71)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹233.89 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Below-Average Return on Equity (0.00%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Limited Institutional Interest (FII+DII: 4.87%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Lincoln Pharmaceuticals Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Lincoln Pharmaceuticals Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
53.3/100
591
₹1183.15
12.3
Average
0.00%
Poor
15.87%
Good
0.0
Excellent
7.11%
Good
10.19%
Good
0.30%
66.4/100
1861
₹446509.73
36.9
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9439
₹250120.25
85.6
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1118
₹111556.44
24.9
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1373
₹110942.04
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1945
₹105078.63
96.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1668
₹95999.74
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1143
₹95440.50
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2078
₹95007.40
17.2
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2238
₹92445.92
45.2
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Lincoln Pharmaceuticals Limited PE Ratio History

Historical price-to-earnings ratio for LINCOLN — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202541.11₹483.9511.8x
FY 202446.58₹787.8016.9x
FY 202336.40₹609.5016.7x
FY 202234.63₹355.5510.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Lincoln Pharmaceuticals Limited Dividend History

Annual cash dividends paid by LINCOLN — dividend yield 0.30%

Financial YearDividends Paid (₹ Cr)
FY 20253.61 Cr
FY 20243.00 Cr
FY 20233.00 Cr
FY 20223.00 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Lincoln Pharmaceuticals Limited Quarterly Performance

Latest quarterly metrics for LINCOLN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

15.07%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

0.43%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

10.19%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

7.11%

Compounded annual net profit growth over 5 years

Lincoln Pharmaceuticals Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for LINCOLN — calculated from daily price history

65RSI 14
Neutral — RSI 65

Momentum is balanced — neither overbought nor oversold.

SMA 50
608
▼ Price below SMA 50 — Short-term bearish
SMA 200
582
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
72K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Lincoln Pharmaceuticals Limited Financial Statements

Annual income statement, balance sheet and cash flow for Lincoln Pharmaceuticals Limited (LINCOLN) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Lincoln Pharmaceuticals Limited

Loading latest quarterly results...

About LINCOLN (Lincoln Pharmaceuticals Limited)

Lincoln Pharmaceuticals Ltd is a dynamic and forward-thinking pharmaceutical company dedicated to enhancing global health through the development, manufacturing, and distribution o...f high-quality medicines. With a strong focus on innovation and patient well-being, Lincoln Pharmaceuticals strives to address diverse medical needs across a wide spectrum of therapeutic areas. The company's state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring the safety and efficacy of its products. Committed to research and development, Lincoln Pharmaceuticals continuously explores new formulations and drug delivery systems to improve treatment outcomes and patient compliance. The company's ethical business practices, coupled with its dedication to social responsibility, solidify its position as a trusted healthcare partner. Lincoln Pharmaceuticals' comprehensive product portfolio encompasses a diverse range of therapeutic categories, catering to various medical conditions and patient populations. From essential medicines addressing common ailments to specialized treatments for chronic diseases, the company's offerings are designed to improve the quality of life for individuals worldwide. A dedicated team of medical professionals and scientists work collaboratively to develop and refine formulations, ensuring optimal therapeutic benefits. By leveraging cutting-edge technology and adhering to rigorous quality control measures, Lincoln Pharmaceuticals consistently delivers safe, effective, and affordable medicines to meet the evolving healthcare needs of the global community. Beyond its domestic operations, Lincoln Pharmaceuticals has established a robust international presence, exporting its products to numerous countries across diverse continents. This global reach reflects the company's commitment to making quality healthcare accessible to people around the world. By forging strategic partnerships and navigating complex regulatory landscapes, Lincoln Pharmaceuticals continues to expand its market presence and contribute to the advancement of healthcare in emerging and developed economies alike. The company's unwavering dedication to quality, innovation, and patient-centricity positions it as a reliable and trusted provider of pharmaceutical solutions on a global scale.

Company Details

Symbol:LINCOLN
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mahendrabhai Gulabdas Patel B.A, LLB
MD & Whole Time Director
Mr. Darshit Ashvinkumar Shah
Chief Financial Officer
Ms. Trusha Kashish Shah
Company Secretary & Compliance Officer

LINCOLN Share Price: Frequently Asked Questions

What is the current share price of Lincoln Pharmaceuticals Limited?

Lincoln Pharmaceuticals Limited (LINCOLN) trades at ₹590.70 on NSE and BSE. Market cap ₹1.18K (Cr). Educational data only.

What is the P/E ratio of Lincoln Pharmaceuticals Limited?

Lincoln Pharmaceuticals Limited has a P/E of 12.27x vs industry average 34.89x.

What is the Bull Run score for Lincoln Pharmaceuticals Limited?

Lincoln Pharmaceuticals Limited has a Bull Run score of 53.3/100 based on 25+ financial parameters.

Does Lincoln Pharmaceuticals Limited pay dividends?

Lincoln Pharmaceuticals Limited has a dividend yield of 0.30%. Past dividends don't guarantee future payments.

What is the ROE of Lincoln Pharmaceuticals Limited?

Lincoln Pharmaceuticals Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Lincoln Pharmaceuticals Limited?

Lincoln Pharmaceuticals Limited has debt-to-equity of 0.01.

Is Lincoln Pharmaceuticals Limited a good investment?

Bull Run gives Lincoln Pharmaceuticals Limited a score of 53.3/100. This is not investment advice — consult a SEBI-registered advisor.